Keyword: Sandostatin


6. Sandostatin LAR

Despite losing its patent protection early in the year, Novartis' Sandostatin LAR is expected to continue chipping in meaningful sales at the Swiss drugmaker for years to come, EvaluatePharma says.
Patents on file

Top 10 U.S. patent losses of 2017

Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top drugmakers. Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead Sciences are set to hit the patent cliff this year with some of their respective big sellers.